Getting Quicker Answers On The Presence Of PAD

Danielle Chicano, Editorial Associate

The statistics on peripheral arterial disease (PAD) are staggering. The Centers for Disease Control and Prevention estimate that approximately 8 million people in the United States have PAD. This includes 12 to 20 percent of people over the age of 60. Accordingly, appropriate testing for this condition is essential.

   BioMedix has developed PADnet, which offers an automated means of obtaining ankle-brachial index (ABI)/toe-brachial index (TBI) values and pulse volume recording (PVR) waveforms. This easy-to use, 10- to 20-minute test can help identify obstructive disease in patients and determine whether medical or surgical treatment is necessary, according to BioMedix.

   BioMedix highlights PADnet’s ease and timeliness, noting that one can send test results instantly to a vascular specialist for interpretation. Specialists can review results at their convenience from any secure Internet connection in the world. Not only does the system ensure both speed and error-free transmission, it does so while maintaining HIPAA compliance, explains the company.

   Farshid Nejad, DPM, FACFAS, notes he has been using PADnet for approximately three years, adding that its usefulness, ease and consistency are advantages that help PADnet outshine similar devices.

   “We were using another device but it was too cumbersome and time consuming so at times, we would refer out so we didn’t tie up our exam rooms,” explains Dr. Nejad. “We use PADnet more frequently than we did our previous device, yielding a win-win situation for the patient and our practice.”

   The device self-calibrates before each use and provides numerical and graphical readings, which the physician can easily and effectively communicate to the patient, adds Dr. Nejad, a Fellow of the American Professional Wound Care Association.

   Not only can physicians easily communicate results to patients, PADnet helps facilitate patient adherence, allowing for routine testing with the system annually, notes Angela L. Drury, DPM, FACFAS. “I use PAD testing for all my diabetic patients, especially when evaluating them for the vascular component of comprehensive diabetic foot exam,” explains Dr. Drury, who is in practice in Albuquerque, N.M. “I also use PADnet for any patient that is seeing me for foot care and is in the age group of risk for PAD.”

   According to Dr. Drury, PADnet allows her to incorporate the highest level of patient care and she emphasizes its importance when evaluating the vascular component of the comprehensive diabetic foot examination.

   With the multitude of advantages using PADnet, Dr. Nejad notes it is a great asset to his practice. “PADnet is well worth the investment as we are doing more exams in less time. This makes the patient feel more at ease when the exam is short and sweet,” explains Dr. Nejad. “Because the device requires less involvement from the operator, there is less user error and more consistent results.”


Thanks to Dr. Drury and Dr. Nejad for sharing their experiences and reinforcing how easy and important it is to test for peripheral arterial disease (PAD) in the podiatric care setting with PADnet.

There are a couple of points in the article that we feel could benefit from some further clarification.

Though it is easy to use and intuitive, the PADnet system is not an “automated” test (it won’t perform itself). The PADnet software provides a step-by-step testing sequence to guide the user through recording ankle-brachial index (ABI) values, toe-brachial index (TBI) values and pulse volume recording (PVR) waveforms. Recording oscillometry and air-cuff plethysmography are used to calculate ABI and PVR measurements via automated algorithms. The accessibility of the cuff-based PADnet testing method and user-friendly software helps reduce technician dependency and deliver more consistent results.

PADnet supports HIPAA compliance by providing data encryption and a secure means to transmit patient demographics and test data directly to an interpreting specialist. However, it is up to each individual practice to ensure it is maintaining and executing complete HIPAA compliance policies and procedures.

With approved physical signs and symptoms, PADnet tests meet reimbursement requirements. Typically, routine screening tests for PAD are not reimbursable. BioMedix makes finding patients with applicable risk factors and indications easier by supplying patient questionnaires and education materials with the system.

Thank you for being a part of the BioMedix collaborative care network and helping to find vascular disease sooner. We look forward to continuing to support the podiatric community as the front line of defense against the progression of PAD through earlier detection and coordinated care.

Add new comment